Dermata Therapeutics, Inc.
DRMA
$1.21
-$0.02-1.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 81.56% | 12.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.44% | 1.37% | |||
| Operating Income | -56.44% | -1.37% | |||
| Income Before Tax | -60.58% | 0.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -60.58% | 0.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -60.58% | 0.76% | |||
| EBIT | -56.44% | -1.37% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -54.07% | 70.92% | |||
| Normalized Basic EPS | -54.06% | 70.92% | |||
| EPS Diluted | -54.07% | 70.92% | |||
| Normalized Diluted EPS | -54.06% | 70.92% | |||
| Average Basic Shares Outstanding | 4.23% | 241.28% | |||
| Average Diluted Shares Outstanding | 4.23% | 241.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||